News Detail
Bagsværd, Denmark, 21 Oct 2024: As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.
Oral semaglutide, sold as Ryb......
View Details
Source : Fierce Pharma
Novo Nordisk
cardiovascular outcomes
Rybelsus
GLP-1
semaglutide
clinical trial data
Clinical Data
Fierce Pharma Homepage
Pharma
Related News
- Police seize 1075 kg of caffeine anhydrous IP worth Rs 19.88 lakh in Zokhawthar (25-10-2024)
- US FDA says PalinGen products are unapproved drugs (25-10-2024)
- CSIR develops device to run health diagnostics, test adulteration (25-10-2024)
- e-mitra Operator and Kingpin distributed 700 fake degrees in 2 years and collected Rs 10 crore (25-10-2024)
- Ephedrine, raw materials to make drug seized in Akola district; five held (25-10-2024)
- Licence of ‘Insulin’ homeopathic tablets cancelled (25-10-2024)
- CDSCO Publishes Alert For failed samples of September 2024 (25-10-2024)
- Drug mafia in Agra revealed secret of supplies (25-10-2024)
- 271 narcotic cough syrups brought in a car seized, two arrested (24-10-2024)
- Merck buys cancer therapeutics maker Modifi for $1.3bn (24-10-2024)